BioSpace News Archive

Tevogen Bio Inc. and Semper Paratus Acquisition Corporation today announced the execution of a merger agreement (the “Merger Agreement”).

XORTX Therapeutics Inc. is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Wednesday, June 28, 2023.

PolyPid Ltd. today announced a new publication highlighting the potent antibacterial activity of D-PLEX100 and its potential as an effective prophylactic drug against the most prevalent bacteria causing surgical site infections (SSIs), including resistant strains.

Akebia Therapeutics ® , Inc. today announced topline results from IMPACT, a Phase 4 collaborative study investigating the impact of Auryxia®.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycemia indications.

Eurofins Genomics Blue Heron is thrilled to announce the launch of our cutting-edge IVT mRNA Synthesis Service.

IntraBio Announces Positive Pivotal Trial Results of IB1001 for the Treatment of Niemann-Pick Disease Type C Phase 3 trial met the primary endpoint and key secondary endpoints showing high statistical significance.

MEI Pharma, Inc. issued the following letter to shareholders reiterating the Board of Directors recommendation to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. in connection with the Company’s special meeting on July 14, 2023.

Sangamo Therapeutics, Inc. and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties have entered into a definitive license agreement for a potential treatment of prion disease.

Exscientia plc (Nasdaq: EXAI) announced today that it is expanding its technology management structure to accelerate application of Exscientia’s innovative technologies to catalyse instrumental change in the way drug candidates are being discovered, designed and developed for patients in need of innovative therapies.